Syndax Pharmaceuticals, Inc. Comprehensive Income
Syndax Pharmaceuticals, Inc. (SNDX) reported Comprehensive Income of -$285.13 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-02-26
- Syndax Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-12-31 was -$94.59M.
- Syndax Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-09-30 was -$82.94M.
- Syndax Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-06-30 was -$68.12M.
- Syndax Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-03-31 was -$73.37M.
- Syndax Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$285.13M.
- Syndax Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$318.81M.
- Syndax Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$208.34M.
- Syndax Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$150.19M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$285.13M 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | -$94.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$177.53M derived: sum of 2 quarters · filed 2026-02-26 | -$245.66M derived: sum of 3 quarters · filed 2026-02-26 | -$318.81M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$82.94M 10-Q · filed 2024-11-05 | -$151.06M derived: sum of 2 quarters · filed 2024-11-05 | -$224.22M 10-Q · filed 2024-11-05 | -$296.24M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | -$68.12M 10-Q · filed 2024-08-01 | -$141.28M 10-Q · filed 2024-08-01 | -$213.30M derived: sum of 3 quarters · filed 2026-02-26 | -$264.32M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | -$73.37M 10-Q · filed 2024-05-08 | -$145.17M derived: sum of 2 quarters · filed 2026-02-26 | -$196.20M derived: sum of 3 quarters · filed 2026-02-26 | -$241.05M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | -$71.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$122.83M derived: sum of 2 quarters · filed 2026-02-26 | -$167.68M derived: sum of 3 quarters · filed 2026-02-26 | -$208.34M 10-K · filed 2026-02-26 | |
| 2023-09-30 | -$51.03M 10-Q · filed 2024-11-05 | -$95.88M derived: sum of 2 quarters · filed 2024-11-05 | -$136.54M 10-Q · filed 2024-11-05 | -$174.93M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | -$44.85M 10-Q · filed 2024-08-01 | -$85.51M 10-Q · filed 2024-08-01 | -$123.90M derived: sum of 3 quarters · filed 2025-03-03 | -$159.58M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | -$40.66M 10-Q · filed 2024-05-08 | -$79.05M derived: sum of 2 quarters · filed 2025-03-03 | -$114.72M derived: sum of 3 quarters · filed 2025-03-03 | -$152.99M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2022-12-31 | -$38.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$74.07M derived: sum of 2 quarters · filed 2025-03-03 | -$112.33M derived: sum of 3 quarters · filed 2025-03-03 | -$150.19M 10-K · filed 2025-03-03 | |
| 2022-09-30 | -$35.67M 10-Q · filed 2023-11-02 | -$73.94M derived: sum of 2 quarters · filed 2023-11-02 | -$111.79M 10-Q · filed 2023-11-02 | -$65.51M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | -$38.27M 10-Q · filed 2023-08-03 | -$76.12M 10-Q · filed 2023-08-03 | -$29.84M derived: sum of 3 quarters · filed 2024-02-27 | -$50.48M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | -$37.85M 10-Q · filed 2023-05-08 | $8.43M derived: sum of 2 quarters · filed 2024-02-27 | -$12.22M derived: sum of 3 quarters · filed 2024-02-27 | -$35.12M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $46.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $25.64M derived: sum of 2 quarters · filed 2024-02-27 | $2.73M derived: sum of 3 quarters · filed 2024-02-27 | -$24.98M 10-K · filed 2024-02-27 | $24.98M 10-K · filed 2022-03-01 |
| 2021-09-30 | -$20.64M 10-Q · filed 2022-11-03 | -$43.55M derived: sum of 2 quarters · filed 2022-11-03 | -$71.26M 10-Q · filed 2022-11-03 | -$91.74M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | -$22.90M 10-Q · filed 2022-08-08 | -$50.61M 10-Q · filed 2022-08-08 | -$71.09M derived: sum of 3 quarters · filed 2023-02-28 | -$91.59M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | -$27.71M 10-Q · filed 2022-05-09 | -$48.19M derived: sum of 2 quarters · filed 2023-02-28 | -$68.69M derived: sum of 3 quarters · filed 2023-02-28 | -$85.68M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | -$20.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$40.98M derived: sum of 2 quarters · filed 2023-02-28 | -$57.97M derived: sum of 3 quarters · filed 2023-02-28 | -$73.16M 10-K · filed 2023-02-28 | |
| 2020-09-30 | -$20.50M 10-Q · filed 2021-11-15 | -$37.49M derived: sum of 2 quarters · filed 2021-11-15 | -$52.68M 10-Q · filed 2021-11-15 | -$66.71M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | -$16.99M 10-Q · filed 2021-08-09 | -$32.18M 10-Q · filed 2021-08-09 | -$46.21M derived: sum of 3 quarters · filed 2022-03-01 | -$59.07M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | -$15.19M 10-Q · filed 2021-05-11 | -$29.21M derived: sum of 2 quarters · filed 2022-03-01 | -$42.08M derived: sum of 3 quarters · filed 2022-03-01 | -$56.94M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2019-12-31 | -$14.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$26.89M derived: sum of 2 quarters · filed 2022-03-01 | -$41.75M derived: sum of 3 quarters · filed 2022-03-01 | -$56.02M 10-K · filed 2022-03-01 | |
| 2019-09-30 | -$12.86M 10-Q · filed 2020-11-05 | -$27.73M derived: sum of 2 quarters · filed 2020-11-05 | -$42.00M 10-Q · filed 2020-11-05 | -$60.82M derived: sum of 4 quarters · filed 2021-03-12 | |
| 2019-06-30 | -$14.87M 10-Q · filed 2020-08-06 | -$29.14M 10-Q · filed 2020-08-06 | -$47.96M derived: sum of 3 quarters · filed 2021-03-12 | -$65.25M derived: sum of 4 quarters · filed 2021-03-12 | |
| 2019-03-31 | -$14.27M 10-Q · filed 2020-05-07 | -$33.10M derived: sum of 2 quarters · filed 2021-03-12 | -$50.38M derived: sum of 3 quarters · filed 2021-03-12 | -$68.64M derived: sum of 4 quarters · filed 2021-03-12 | |
| 2018-12-31 | -$18.83M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$36.11M derived: sum of 2 quarters · filed 2021-03-12 | -$54.37M derived: sum of 3 quarters · filed 2021-03-12 | -$73.84M 10-K · filed 2021-03-12 | |
| 2018-09-30 | -$17.28M 10-Q · filed 2019-11-07 | -$35.54M derived: sum of 2 quarters · filed 2019-11-07 | -$55.02M 10-Q · filed 2019-11-07 | -$74.29M derived: sum of 4 quarters · filed 2020-03-05 | |
| 2018-06-30 | -$18.26M 10-Q · filed 2019-08-07 | -$37.73M 10-Q · filed 2019-08-07 | -$57.01M derived: sum of 3 quarters · filed 2020-03-05 | -$72.10M derived: sum of 4 quarters · filed 2020-03-05 | |
| 2018-03-31 | -$19.47M 10-Q · filed 2019-05-08 | -$38.75M derived: sum of 2 quarters · filed 2020-03-05 | -$53.84M derived: sum of 3 quarters · filed 2020-03-05 | -$67.44M derived: sum of 4 quarters · filed 2020-03-05 | |
| 2017-12-31 | -$19.27M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | -$34.37M derived: sum of 2 quarters · filed 2020-03-05 | -$47.97M derived: sum of 3 quarters · filed 2020-03-05 | -$61.00M 10-K · filed 2020-03-05 | |
| 2017-09-30 | -$15.10M 10-Q · filed 2018-11-05 | -$28.70M derived: sum of 2 quarters · filed 2018-11-05 | -$41.73M 10-Q · filed 2018-11-05 | -$52.59M derived: sum of 4 quarters · filed 2019-03-07 | |
| 2017-06-30 | -$13.60M 10-Q · filed 2018-08-08 | -$26.63M 10-Q · filed 2018-08-08 | -$37.49M derived: sum of 3 quarters · filed 2019-03-07 | -$52.55M derived: sum of 4 quarters · filed 2019-03-07 | |
| 2017-03-31 | -$13.03M 10-Q · filed 2018-05-09 | -$23.89M derived: sum of 2 quarters · filed 2019-03-07 | -$38.95M derived: sum of 3 quarters · filed 2019-03-07 | -$47.34M derived: sum of 4 quarters · filed 2019-03-07 | |
| 2016-12-31 | -$10.86M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$25.92M derived: sum of 2 quarters · filed 2019-03-07 | -$34.31M derived: sum of 3 quarters · filed 2019-03-07 | -$44.44M 10-K · filed 2019-03-07 | |
| 2016-09-30 | -$15.06M 10-Q · filed 2017-11-08 | -$23.45M derived: sum of 2 quarters · filed 2017-11-08 | -$33.59M 10-Q · filed 2017-11-08 | -$38.84M derived: sum of 4 quarters · filed 2018-03-08 | |
| 2016-06-30 | -$8.39M 10-Q · filed 2017-08-10 | -$18.52M 10-Q · filed 2017-08-10 | -$23.78M derived: sum of 3 quarters · filed 2018-03-08 | -$31.48M derived: sum of 4 quarters · filed 2018-03-08 | |
| 2016-03-31 | -$10.13M 10-Q · filed 2017-05-09 | -$15.38M derived: sum of 2 quarters · filed 2018-03-08 | -$23.09M derived: sum of 3 quarters · filed 2018-03-08 | -$29.31M derived: sum of 4 quarters · filed 2018-03-08 | |
| 2015-12-31 | -$5.25M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$12.96M derived: sum of 2 quarters · filed 2018-03-08 | -$19.18M derived: sum of 3 quarters · filed 2018-03-08 | -$24.09M 10-K · filed 2018-03-08 | |
| 2015-09-30 | -$7.71M 10-Q · filed 2016-11-14 | -$13.93M derived: sum of 2 quarters · filed 2016-11-14 | -$18.84M 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | -$6.22M 10-Q · filed 2016-08-15 | -$11.13M 10-Q · filed 2016-08-15 | |||
| 2015-03-31 | -$4.91M 10-Q · filed 2016-05-16 | ||||
| 2014-12-31 | -$19.83M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |